{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:19:28Z","timestamp":1781277568576,"version":"3.54.1"},"reference-count":138,"publisher":"Elsevier","isbn-type":[{"value":"9780443297229","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.05.001","type":"book-chapter","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:07:12Z","timestamp":1759842432000},"page":"83-112","source":"Crossref","is-referenced-by-count":2,"title":["Traditional treatments and different geographical approaches"],"prefix":"10.1016","member":"78","reference":[{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","article-title":"The effect of cyclophosphamide on the immune system: Implications for clinical cancer therapy","volume":"78","author":"Ahlmann","year":"2016","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/ene.14547","article-title":"Chronic immunoglobulin maintenance therapy in myasthenia gravis","volume":"28","author":"Alcantara","year":"2021","journal-title":"European Journal of Neurology"},{"issue":"2\u20133","key":"10.1016\/bs.irn.2025.05.001_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"issue":"2 Pt 2","key":"10.1016\/bs.irn.2025.05.001_bib4","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/0090-1229(89)90083-4","article-title":"Experience with intravenous immunoglobulin in myasthenia gravis","volume":"53","author":"Arsura","year":"1989","journal-title":"Clinical Immunology and Immunopathology"},{"issue":"12","key":"10.1016\/bs.irn.2025.05.001_bib5","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","article-title":"High-dose intravenous methylprednisolone in myasthenia gravis","volume":"42","author":"Arsura","year":"1985","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/imi.0000000000000490","article-title":"Thymectomy for nonthymomatous myasthenia gravis: Comparison of video-assisted thoracoscopic and transsternal thymectomy","volume":"13","author":"Bagheri","year":"2018","journal-title":"Innovations (Philadelphia, Pa. )"},{"key":"10.1016\/bs.irn.2025.05.001_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2024-333920","article-title":"Cyclophosphamide for myasthenia gravis: A comeback?","author":"Barnett-Tapia","year":"2024","journal-title":"Journal of Neurology, Neurosurgery, And Psychiatry"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1212\/01.wnl.0000324254.97372.e0","article-title":"The muddle of mycophenolate mofetil in myasthenia","volume":"71","author":"Benatar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.05.001_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221122538","article-title":"Remission and relapses of myasthenia gravis on long-term tacrolimus: A retrospective cross-sectional study of a Chinese cohort","volume":"13","author":"Bi","year":"2022","journal-title":"Therapeutic Advances in Chronic Disease"},{"key":"10.1016\/bs.irn.2025.05.001_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","article-title":"An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts","volume":"13","author":"Boldingh","year":"2015","journal-title":"Health and Quality of Life Outcomes"},{"issue":"12","key":"10.1016\/bs.irn.2025.05.001_bib11","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/0003-4819-154-12-201106210-00009","article-title":"Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: A systematic review","volume":"154","author":"Booth","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib12","first-page":"65","article-title":"Genetic polymorphisms of thiopurine methyltransferase and incidence of adverse events in patients with medical indication of azathioprine","volume":"78","author":"Buhl","year":"2018","journal-title":"Medicina"},{"key":"10.1016\/bs.irn.2025.05.001_bib13","doi-asserted-by":"crossref","first-page":"8719284","DOI":"10.1155\/2020\/8719284","article-title":"The effects of alternate-day corticosteroids in autoimmune disease patients","volume":"2020","author":"Chaia-Semerena","year":"2020","journal-title":"Autoimmune Diseases"},{"issue":"12","key":"10.1016\/bs.irn.2025.05.001_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2023-333189","article-title":"Induction cyclophosphamide with maintenance immunosuppression in high-risk myasthenia gravis: Long-term follow-up and safety profile","volume":"95","author":"Chan","year":"2024","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2025.05.001_bib16","first-page":"963","article-title":"Population PK\/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients","volume":"12","author":"Chen","year":"2023","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: An open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib18","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.55.3.448","article-title":"Retrospective analysis of the use of cyclosporine in myasthenia gravis","volume":"55","author":"Ciafaloni","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis","volume":"59","author":"Clifford","year":"2019","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nature Reviews Rheumatology"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1756285615571873","article-title":"The emerging role of tacrolimus in myasthenia gravis","volume":"8","author":"Cruz","year":"2015","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1016\/bs.irn.2025.05.001_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pediatrneurol.2023.07.024","article-title":"Measuring the efficacy of thymectomy for pediatric myasthenia gravis across tertiary Children\u2019s hospitals","volume":"148","author":"De Boer","year":"2023","journal-title":"Pediatric Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/mus.21997","article-title":"PCP chemoprophylaxis is essential for lymphopenic dermatomyositis patients treated with immunomodulators","volume":"43","author":"Efthimiou","year":"2011","journal-title":"Muscle & Nerve"},{"issue":"8","key":"10.1016\/bs.irn.2025.05.001_bib26","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1200\/JCO.2001.19.8.2293","article-title":"Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine","volume":"19","author":"Evans","year":"2001","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/acn3.51746","article-title":"Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis","volume":"10","author":"Fan","year":"2023","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/bs.irn.2025.05.001_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.594152","article-title":"Favorable effects of tacrolimus monotherapy on myasthenia gravis patients","volume":"11","author":"Fan","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurologic Clinics"},{"key":"10.1016\/bs.irn.2025.05.001_bib30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"8381","key":"10.1016\/bs.irn.2025.05.001_bib31","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(84)92294-3","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Fateh-Moghadam","year":"1984","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/bs.irn.2025.05.001_bib32","first-page":"781","article-title":"Cyclophosphamide toxicity","volume":"42","author":"Fraiser","year":"1991","journal-title":"Characterising and Avoiding the Problem. Drugs"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib33","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.05.001_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"European Journal of Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2025.05.001_bib35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"The Lancet Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.05.001_bib36","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/bs.irn.2025.05.001_bib37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"369","author":"Gotterer","year":"2016","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle & Nerve"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib39","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","author":"Group","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1600-0404.2003.00209.x","article-title":"Response of thymectomy: Clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients","volume":"109","author":"Guillermo","year":"2004","journal-title":"Acta Neurologica Scandinavica"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s13311-015-0398-y","article-title":"Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis","volume":"13","author":"Guptill","year":"2016","journal-title":"Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib42","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.clinph.2008.10.138","article-title":"120. Methotrexate in myasthenia gravis","volume":"120","author":"Hartmann","year":"2009","journal-title":"Clinical Neurophysiology"},{"key":"10.1016\/bs.irn.2025.05.001_bib43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.05.001_bib44","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.nmd.2013.09.013","article-title":"Outcome of children with acetylcholine receptor (AChR) antibody positive juvenile myasthenia gravis following thymectomy","volume":"24","author":"Heng","year":"2014","journal-title":"Neuromuscular Disorders: NMD"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib46","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/WNL.38.2.258","article-title":"Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis","volume":"38","author":"Hohlfeld","year":"1988","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ana.410170304","article-title":"Myasthenia gravis: Reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine","volume":"17","author":"Hohlfeld","year":"1985","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1749-6632.1976.tb47718.x","article-title":"Alternate-day prednisone: Preliminary report of a double-blind controlled study","volume":"274","author":"Howard","year":"1976","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.05.001_bib49","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1749-6632.1976.tb47718.x","article-title":"Alternate-day prednisone: Preliminary report of a double-blind controlled study","volume":"274","author":"Howard","year":"1976","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12883-022-02593-6","article-title":"Spotlight on MuSK positive myasthenia gravis: Clinical characteristics, treatment and outcomes","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib51","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.nmd.2021.02.010","article-title":"Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis","volume":"31","author":"Itani","year":"2021","journal-title":"Neuromuscular Disorders: NMD"},{"key":"10.1016\/bs.irn.2025.05.001_bib52","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.933296","article-title":"Adverse side effects associated with corticosteroid therapy: A study in 39 patients with generalized myasthenia gravis","volume":"27","author":"Johnson","year":"2021","journal-title":"Medical Science Monitor: International Medical Journal of Experimental and Clinical Research"},{"issue":"12","key":"10.1016\/bs.irn.2025.05.001_bib53","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209482","article-title":"Does surgical removal of the thymus have deleterious consequences?","volume":"102","author":"Kaminski","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib54","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ene.13189","article-title":"Adequate tacrolimus concentration for myasthenia gravis treatment","volume":"24","author":"Kanai","year":"2017","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.05.001_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2018.10.018","article-title":"Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis","volume":"396","author":"Kanai","year":"2019","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/bs.irn.2025.05.001_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108303","article-title":"The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis","volume":"182","author":"Katz","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2025.05.001_bib57","series-title":"Farmacolog\u00eda b\u00e1sica y cl\u00ednica","author":"Katzung","year":"2019"},{"issue":"10","key":"10.1016\/bs.irn.2025.05.001_bib58","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.clineuro.2007.08.006","article-title":"Effects of thymectomy on late-onset myasthenia gravis without thymoma","volume":"109","author":"Kawaguchi","year":"2007","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"8","key":"10.1016\/bs.irn.2025.05.001_bib59","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079904125004385","article-title":"Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis","volume":"20","author":"Kawaguchi","year":"2004","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib60","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00415-019-09222-2","article-title":"Effect of thymectomy in elderly patients with non-thymomatous generalized myasthenia gravis","volume":"266","author":"Kim","year":"2019","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib61","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus","volume":"76","author":"Konishi","year":"2005","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2025.05.001_bib62","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mus.10472","article-title":"Clinical study of FK506 in patients with myasthenia gravis","volume":"28","author":"Konishi","year":"2003","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Archives of Neurology"},{"issue":"7726","key":"10.1016\/bs.irn.2025.05.001_bib64","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0140-6736(71)92268-9","article-title":"Cyclophosphamide and organ transplantation","volume":"2","author":"Lanari","year":"1971","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib65","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis","volume":"64","author":"Lauriola","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib66","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3988\/jcn.2016.12.4.482","article-title":"Clinical significance of repetitive compound muscle action potentials in patients with myasthenia gravis: A predictor for cholinergic side effects of acetylcholinesterase inhibitors","volume":"12","author":"Lee","year":"2016","journal-title":"Journal of Clinical Neurology (Seoul, Korea)"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib67","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient\u2019s perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"Journal of Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2025.05.001_bib68","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u201cseronegative\u201d myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib69","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Annals of Neurology"},{"issue":"0","key":"10.1016\/bs.irn.2025.05.001_bib70","first-page":"1","article-title":"China guidelines for the diagnosis and treatment of myasthenia gravis","volume":"3","author":"Li","year":"2016","journal-title":"Neurosciences"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib71","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: A double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurologica Scandinavica"},{"issue":"8","key":"10.1016\/bs.irn.2025.05.001_bib72","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s004150050135","article-title":"Outcome in juvenile-onset myasthenia gravis: A retrospective study with long-term follow-up of 79 patients","volume":"244","author":"Lindner","year":"1997","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.05.001_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116734","article-title":"Myasthenia gravis and azathioprine treatment: Adverse events related to thiopurine S-methyl-transferase (TPMT) polymorphisms","volume":"412","author":"Lorenzoni","year":"2020","journal-title":"Journal of the Neurological Sciences"},{"issue":"8","key":"10.1016\/bs.irn.2025.05.001_bib74","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00314245","article-title":"Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis","volume":"235","author":"Mantegazza","year":"1988","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib75","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ejcts\/ezy075","article-title":"Comparing robotic and trans-sternal thymectomy for early-stage thymoma: A propensity score-matching study","volume":"54","author":"Marulli","year":"2018","journal-title":"European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery"},{"key":"10.1016\/bs.irn.2025.05.001_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577850","article-title":"The clinical need for clustered AChR cell-based assay testing of seronegative MG","volume":"367","author":"Masi","year":"2022","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.05.001_bib77","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1749-6632.1987.tb51327.x","article-title":"Immunosuppressive drugs: Azathioprine in the treatment of myasthenia gravis","volume":"505","author":"Matell","year":"1987","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","article-title":"Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis","volume":"23","author":"Mee","year":"2003","journal-title":"Journal of Neuro-Ophthalmology: The Official Journal of the North American Neuro-Ophthalmology Society"},{"issue":"10","key":"10.1016\/bs.irn.2025.05.001_bib79","doi-asserted-by":"crossref","first-page":"CD006986","DOI":"10.1002\/14651858.CD006986.pub3","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","volume":"2014","author":"Mehndiratta","year":"2014","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1016\/bs.irn.2025.05.001_bib80","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: A supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"Journal of Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib81","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209722","article-title":"Effect of immunosuppression in risk of developing generalized symptoms in ocular myasthenia gravis: A retrospective cohort study","volume":"103","author":"Menon","year":"2024","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2025.05.001_bib82","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: An analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.05.001_bib83","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1196\/annals.1254.064","article-title":"Mycophenolate mofetil for myasthenia gravis: A double-blind, placebo-controlled pilot study","volume":"998","author":"Meriggioli","year":"2003","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.05.001_bib84","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1749-6632.1981.tb33767.x","article-title":"Effect of immunosuppressive drugs (azathioprine)","volume":"377","author":"Mertens","year":"1981","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib85","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.athoracsur.2008.11.040","article-title":"Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches","volume":"87","author":"Meyer","year":"2009","journal-title":"The Annals of Thoracic Surgery"},{"issue":"5","key":"10.1016\/bs.irn.2025.05.001_bib86","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.36.5.729","article-title":"Prednisone-induced worsening of neuromuscular function in myasthenia gravis","volume":"36","author":"Miller","year":"1986","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib87","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib88","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: Putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clinical and Experimental Neuroimmunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib89","first-page":"7","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome: An overview","volume":"76","author":"Murai","year":"2024","journal-title":"Brain and Nerve = Shinkei Kenkyu no Shinpo"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib90","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.13544","article-title":"Rationale for the clinical guidelines for myasthenia gravis in Japan","volume":"1413","author":"Murai","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"5","key":"10.1016\/bs.irn.2025.05.001_bib91","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Archives of Ophthalmology (Chicago, Ill.: 1960)"},{"issue":"8","key":"10.1016\/bs.irn.2025.05.001_bib92","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2169\/internalmedicine.47.0513","article-title":"Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus","volume":"47","author":"Nagaishi","year":"2008","journal-title":"Internal Medicine (Tokyo, Japan)"},{"key":"10.1016\/bs.irn.2025.05.001_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013278","article-title":"Social disadvantages associated with myasthenia gravis and its treatment: A multicentre cross-sectional study","volume":"7","author":"Nagane","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib94","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000319172","article-title":"Two-year treatment with cyclosporine microemulsion for responder myasthenia gravis patients","volume":"64","author":"Nagane","year":"2010","journal-title":"European Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib95","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000322497","article-title":"Early aggressive treatment strategy against myasthenia gravis","volume":"65","author":"Nagane","year":"2011","journal-title":"European Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib96","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1474-4422(24)00028-0","article-title":"Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): A prospective cohort study","volume":"23","author":"Narayanaswami","year":"2024","journal-title":"The Lancet. Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib97","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib98","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/ene.14039","article-title":"Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis","volume":"27","author":"Nishida","year":"2020","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.05.001_bib99","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3389\/fneur.2020.00743","article-title":"Management of Juvenile Myasthenia gravis","volume":"11","author":"O\u2019Connell","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib100","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib101","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2025.05.001_bib102","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1749-6632.2012.06804.x","article-title":"Phase II trial of methotrexate in myasthenia gravis","volume":"1275","author":"Pasnoor","year":"2012","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"02","key":"10.1016\/bs.irn.2025.05.001_bib104","doi-asserted-by":"crossref","first-page":"E84","DOI":"10.1055\/s-0043-124983","article-title":"Treatment standards and individualized therapy of myasthenia gravis","volume":"2","author":"Paul Urban","year":"2018","journal-title":"Neurology International Open"},{"issue":"1","key":"10.1016\/bs.irn.2025.05.001_bib105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/WNL.31.1.32","article-title":"Stable remissions in myasthenia gravis","volume":"31","author":"Perez","year":"1981","journal-title":"Neurology"},{"issue":"8008","key":"10.1016\/bs.irn.2025.05.001_bib106","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(77)92639-3","article-title":"Plasma exchange in myasthenia gravis","volume":"1","author":"Pinching","year":"1977","journal-title":"Lancet (London, England)"},{"key":"10.1016\/bs.irn.2025.05.001_bib107","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: A clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.05.001_bib108","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: A clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"12","key":"10.1016\/bs.irn.2025.05.001_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7120552","article-title":"Fetal toxicity of immunosuppressive drugs in pregnancy","volume":"7","author":"Ponticelli","year":"2018","journal-title":"Journal of Clinical Medicine"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib110","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12028-021-01259-4","article-title":"Acetylcholinesterase inhibitors in myasthenic crisis: A systematic review of observational studies","volume":"35","author":"Prado","year":"2021","journal-title":"Neurocritical Care"},{"key":"10.1016\/bs.irn.2025.05.001_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-associated myasthenia gravis: Clinical features and management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib112","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.05.001_bib113","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1196\/annals.1405.031","article-title":"Lessons from two trials of mycophenolate mofetil in myasthenia gravis","volume":"1132","author":"Sanders","year":"2008","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib114","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nature Clinical Practice. Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib116","first-page":"CD002828","article-title":"Corticosteroids for myasthenia gravis","volume":"2005","author":"Schneider-Gold","year":"2005","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/bs.irn.2025.05.001_bib117","first-page":"746","article-title":"Thmymektomie bie Einem Fall Von Morbus Basedowi mit Masthenie","volume":"25","author":"Schumacher","year":"1912","journal-title":"Grenzgeb. d. Med. u. Chir"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib118","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM197401102900204","article-title":"Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment","volume":"290","author":"Seybold","year":"1974","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib119","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Practical Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.05.001_bib120","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1212\/WNL.30.5.557","article-title":"Humoral immunity in myasthenia gravis: Effect of steroids and thymectomy","volume":"30","author":"Tindall","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.05.001_bib121","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"12","key":"10.1016\/bs.irn.2025.05.001_bib122","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib123","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/0883073808325653","article-title":"Graded response to thymectomy in children with myasthenia gravis","volume":"24","author":"Tracy","year":"2009","journal-title":"Journal of Child Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib124","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1468-1331.2008.02130.x","article-title":"Monitoring treatment with cyclosporine microemulsion in myasthenia gravis","volume":"15","author":"Utsugisawa","year":"2008","journal-title":"European Journal of Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/mus.24213","article-title":"Health-related quality-of-life and treatment targets in myasthenia gravis","volume":"50","author":"Utsugisawa","year":"2014","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib126","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s13760-022-02162-1","article-title":"Minimal symptom expression achievement over time in generalized myasthenia gravis","volume":"123","author":"Uzawa","year":"2023","journal-title":"Acta Neurologica Belgica"},{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib127","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1212\/01.wnl.0000173031.56429.04","article-title":"Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil","volume":"65","author":"Vernino","year":"2005","journal-title":"Neurology"},{"issue":"5779","key":"10.1016\/bs.irn.2025.05.001_bib128","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0140-6736(00)94294-6","article-title":"Treatment of myasthenia gravis with physiostigmine","volume":"223","author":"Walker","year":"1934","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/bs.irn.2025.05.001_bib129","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","article-title":"Efficacy and safety of tacrolimus for myasthenia gravis: A systematic review and meta-analysis","volume":"264","author":"Wang","year":"2017","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.05.001_bib130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nmd.2011.08.007","article-title":"Autoimmune myasthenia gravis, immunotherapy and thymectomy in children","volume":"22","author":"Ware","year":"2012","journal-title":"Neuromuscular Disorders: NMD"},{"key":"10.1016\/bs.irn.2025.05.001_bib131","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib132","article-title":"A drug safety briefing (II) in transplantation from real-world individual pharmacotherapy management to prevent patient and graft from polypharmacy risks at the very earliest stage","volume":"17","author":"Wolf","year":"2024","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"4","key":"10.1016\/bs.irn.2025.05.001_bib133","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mus.10224","article-title":"Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis","volume":"26","author":"Wolfe","year":"2002","journal-title":"Muscle & Nerve"},{"issue":"6","key":"10.1016\/bs.irn.2025.05.001_bib134","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.05.001_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","author":"Wolfe","year":"2019","journal-title":"The Lancet Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2025.05.001_bib136","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"3","key":"10.1016\/bs.irn.2025.05.001_bib137","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1600-0404.2006.00733.x","article-title":"The effectiveness of thymectomy on seronegative generalized myasthenia gravis: Comparing with seropositive cases","volume":"115","author":"Yuan","year":"2007","journal-title":"Acta Neurologica Scandinavica"},{"issue":"9","key":"10.1016\/bs.irn.2025.05.001_bib138","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: Randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Therapeutic Advances in Neurological Disorders"}],"container-title":["International Review of Neurobiology","Myasthenia Gravis, Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:58:36Z","timestamp":1760500716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774225000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443297229"],"references-count":138,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.05.001","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}